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Abstract: Background and objectives: Characterization of pediatric coronavirus disease 2019 (COVID-19)
is necessary to control the pandemic, as asymptomatic or mildly infected children may act as carriers.
To date, there are limited reports describing differences in clinical, laboratory, and radiological
characteristics between asymptomatic and symptomatic infection, and between younger and older
pediatric patients. The objective of this study is to compare characteristics among: (1) asymptomatic
versus symptomatic and (2) less than 10 versus greater or equal to 10 years old pediatric COVID-19
patients. Materials and Methods: We searched for all terms related to pediatric COVID-19 in
electronic databases (Embase, Medline, PubMed, and Web of Science) for articles from January 2020.
This protocol followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis
guidelines. Results: Eligible study designs included case reports and series, while we excluded
comments/letters, reviews, and literature not written in English. Initially, 817 articles were identified.
Forty-three articles encompassing 158 confirmed pediatric COVID-19 cases were included in the final
analyses. Lymphocytosis and high CRP were associated with symptomatic infection. Abnormal
chest CT more accurately detected asymptomatic COVID-19 in older patients than in younger ones,
but clinical characteristics were similar between older and younger patients. Conclusions: Chest
CT scan findings are untrustworthy in younger children with COVID-19 as compared with clinical
findings, or significant differences in findings between asymptomatic to symptomatic children.
Medicina 2020, 56, 474; doi:10.3390/medicina56090474 www.mdpi.com/journal/medicina
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Further studies evaluating pediatric COVID-19 could contribute to potential therapeutic interventions
and preventive strategies to limit spreading.
Keywords: coronavirus disease 2019 (COVID-19); novel coronavirus 2019; SARS-CoV-2;
asymptomatic; child; infant; characteristics; radiography
1. Introduction
Since December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which
causes coronavirus disease 2019 (COVID-19) emerged as a virus causing substantial morbidity and
mortality worldwide. There have been over 10 million confirmed cases and over 500,000 deaths
worldwide [1]. The transmission of COVID-19 has been shown to occur during pre-symptomatic or
asymptomatic periods which contribute to widespread transmission of the infection [2].
The reported number of cases worldwide implicates that elderly persons are especially vulnerable
to the disease, contracting from children [3,4]. In addition, most children with COVID-19 have been
reported to present with mild symptoms [5]. However, many studies suggested that children, despite
mild or no symptoms, could be a source of viral transmission [6,7]. It has been reported that the viral
load in asymptomatic patients was similar to that in symptomatic patients, especially during the early
phase of infection [8,9].
There have been some systematic reviews and meta-analyses on COVID-19 aimed at characterizing
SARS-CoV-2 infections in pediatric age groups [10]. However, no study, to date, has focused on
the difference between symptomatic and asymptomatic pediatric patients. Previous studies were
mainly based on information from adult populations and limited data were available for children with
COVID-19 [5,11,12]. Therefore, we conducted a systematic review with the aim to investigate clinical,




The primary goal of this study was to systematically evaluate and characterize reported pediatric
COVID-19 cases. An age threshold of 10 years was selected to distinguish between findings before
and after the onset of puberty, which can vary with ethnicity and gender but generally begins as early
as age 10. Analyses were stratified by clinical characteristics, laboratory findings, and radiological
signs in children with COVID-19 based on this age threshold of 10 years and the presence or absence
of symptoms. For asymptomatic patients, the continued absence of symptoms was also evaluated
when reported at follow-up.
2.2. Search Strategy
The following databases were utilized: Embase, Medline, PubMed, and Web of Science, using the
search terms: “COVID-19”, “SARS-CoV-2”, “novel coronavirus 2019”, “pediatrics”, “child*”, “infant*”,
“neonate*”, and “adolescent*”. Articles were evaluated independently by four different researchers
(D. Kim, H. Im, W. Rha, and E. Kim). The protocol followed the recommendations set forth by the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [13].
2.3. Eligible Criteria
We included peer-reviewed articles that reported confirmed SARS-CoV-2 infections by reverse
transcription polymerase chain reaction. Eligible study designs included case reports and case series.
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Comments/letters and reviews were excluded. Articles not published in English were also excluded.
Articles with duplicate cases were excluded.
2.4. Study Selection and Assessment of Risk of Bias
Initial results were reviewed by screening for duplicates, and then were screened by title and
format for eligibility criteria. After full-text screening, a targeted search was conducted to generate
additional articles focusing on asymptomatic children with COVID-19, using the same method used
for the initial search.
2.5. Data Extraction and Statistical Analysis
Three independent investigators extracted data from each eligible study using a standardized
data extraction form. Data were cross-checked for duplicate articles, duplicate cases, or discrepancies.
Disagreements between reviewers regarding the data were resolved with reviews from three other
independent investigators (E. Kim, S. Cha, and J. Yang). Statistical analyses were performed using
SPSS version 26.0. Power was calculated using G*Power version 3.1.9.6. Percentages and means
± standard deviation were used to summarize categorical and continuous variables, respectively.
The Kolmogorov–Smirnov test was used to test the normal distribution and the Mann–Whitney U
test was used for non-normal distribution variables. The Chi-square test was performed to evaluate
differences between age groups and symptomatic/asymptomatic groups, while the number in each
cell was below 5, Fisher’s exact test was performed, and the student’s T test was used to evaluate
differences in age.
3. Results
Initially, 817 articles were identified in a preliminary search. After screening to exclude duplicates,
673 articles were reviewed by title screening for topic (focusing on pediatric COVID-19), format
(excluding comments and reviews), and language. Of 197 reviewed from full-text screening, 86 were
unrelated to pediatric COVID-19, 41 were not case reports, 31 were letters or reviews, 10 were pooled
patient data, and 4 were inaccessible. An additional search was conducted and resulted in 18 additional
eligible articles. Forty-three articles met all inclusion criteria and were included in final analyses
(Figure 1).
3.1. Study Characteristics and Demographic Features
Of the 33 studies that reported study location, 22 took place in China [6,14–33], five in
Europe [34–38], two in the United States [39,40], and one each in Malaysia [41], Republic of Korea [42],
Vietnam [43], and Singapore [44] (Table 1). A total of 158 cases of pediatric COVID-19 were identified.
All articles reported age at onset of infection. Specifically, 116 children were younger than 10 years
at onset, and 40 were 10–17 years old. Twenty-four studies reported 51 asymptomatic infections
(Table S1) [6,14–20,22,30,32–34,41,44–52], and 30 studies reported 106 cases of symptomatic infections
(Table S2) [15–21,23–32,35–43,45,46,52,53]. Fever was recorded in 78 patients, respiratory symptoms
(such as cough, tachypnea, or pharyngeal congestion) in 74 patients, and gastrointestinal symptoms
(including vomiting and diarrhea) in 27 patients. Other symptoms included malaise, convulsions,
arthralgia, headache, chest pain, fatigue, skin rash, feeding difficulty, decreased oral intake, drowsiness,
and myalgia. Within the symptomatic population, 81 children were below 10 years old, and 25 were
between 10–17 years old. Within the asymptomatic population, 35 were younger than 10. Sex was
reported in 150 cases, and out of these 81 (54.0%) were male. In the 51 asymptomatic patients, follow-up
data were reported in 24 cases (47.0%).
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Figure 1. Flow chart of the literature search. Abbreviation: COVID-19 (coronavirus disease 2019). 
 
Figure 1. Flo chart of the literature search. bbreviation: I -19 (coronavirus disease 2019).
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Table 1. Baseline demographic, clinical characteristics, radiologic and laboratory findings according to symptoms and age group in children 1.
Symptoms Age
Variables Asymptomatic (n = 51) Symptomatic (n = 107) p Value <10 Years (n = 116) ≥10 Years (n = 40) p Value Total (n = 158)
Age (years) 5.84 ± 4.91 5.39 ± 5.20 0.606 3.09 ± 3.21 12.60 ± 1.97 0.000 5.53 ± 5.08
Male 31/47 (66.0%) 50/103 (48.5%) 0.054 56/109 (51.4%) 24/40 (60.0%) 0.362 81/150 (54.0%)
Female 16/47 (34.0%) 53/103 (51.5%) 0.054 47/97 (48.5%) 11/27 (40.7%) 0.519 69/150 (46.0%)
Country (location) 0.000 0.007
China 22/24 (91.7%) 68/96 (70.8%) - 75/91 (82.4%) 14/28 (50.0%) - 90/120 (75.0%)
Europe - 20/96 (20.8%) - 10/91 (11.0%) 10/28 (35.7%) - 20/120 (16.7%)
Malaysia 1/24 (4.2%) 3/96 (3.1%) - 3/91 (3.3%) 1/28 (3.6%) - 4/120 (3.3%)
United States - 3/96 (3.1%) - 1/91 (1.1%) 2/28 (7.1%) - 3/120 (2.5%)
Republic of Korea - 1/96 (1.0%) - - 1/28 (3.6%) - 1/120 (0.8%)
Vietnam - 1/96 (1.0%) - 1/91 (1.1%) - - 1/120 (0.8%)
Singapore 1/24 (4.2%) - - 1/91 (1.1%) - - 1/120 (0.8%)
Asymptomatic during follow-up 23/24 (95.8%) - - 14/14 (100.0%) 8/9 (88.9%) 0.391 23/24 (95.8%)
Radiology abnormal 15/31 (48.4%) 44/69 (63.8%) 0.188 41/75 (54.7%) 17/23 (73.9%) 0.145 59/100 (59.0%)
Typical ground-glass opacities with patchy shadows 4/31 (12.9%) 15/69 (21.7%) 0.411 13/75 (17.3%) 6/23 (26.1%) 0.374 19/100 (19.0%)
Typical ground-glass opacities with consolidation 2/31 (6.5%) 0/69 (0.0%) 0.094 2/75 (2.7%) 0/23 (0.0%) 1.000 2/100 (2.0%)
Typical ground-glass opacities only 3/31 (9.7%) 11/68 (16.2%) 0.539 8/75 (10.7%) 6/22 (27.3%) 0.080 14/99 (14.1%)
Typical ground-glass opacities 10/31 (32.3%) 27/69 (39.1%) 0.655 24/75 (32.0%) 13/23 (56.5%) 0.049 37/100 (37.0%)
Consolidation 0/31 (0.0%) 3/69 (4.3%) 0.550 2/75 (2.7%) 1/23 (4.3%) 1.000 3/100 (3.0%)
Signs of pneumonia 14/31 (45.2%) 43/69 (62.3%) 0.129 39/75 (52.0%) 17/23 (73.9%) 0.091 57/100 (57.0%)
Bronchitis 1/31 (3.2%) 1/69 (1.4%) 1.000 2/75 (2.7%) 0/23 (0.0%) 1.000 2/100 (2.0%)
Laboratory abnormal 17/31 (54.8%) 61/93 (65.6%) 0.104 63/95 (66.3%) 14/31 (45.2%) 0.055 78/128 (60.9%)
WBC count, high 2/35 (5.7%) 11/93 (11.8%) 0.356 12/95 (12.6%) 1/31 (3.2%) 0.184 13/128 (10.2%)
low 1/35 (2.9%) 13/93 (14.0%) 0.110 9/95 (9.5%) 5/31 (16.1%) 0.330 14/128 (10.9%)
Neutrophil count, high 0/33 (0.0%) 5/86 (5.8%) 0.320 3/88 (3.4%) 2/29 (6.9%) 0.596 5/119 (4.2%)
low 2/33 (6.1%) 15/86 (17.4%) 0.148 13/88 (14.8%) 3/29 (10.3%) 0.758 17/119 (14.3%)
Lymphocyte count, high 0/35 (0.0%) 13/93 (14.0%) 0.019 11/95 (11.6%) 1/31 (3.2%) 0.291 13/128 (10.2%)
low 1/35 (2.9%) 10/93 (10.8%) 0.185 10/95 (10.5%) 1/31 (3.2%) 0.291 11/128 (8.6%)
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Table 1. Cont.
Symptoms Age
Variables Asymptomatic (n = 51) Symptomatic (n = 107) p Value <10 Years (n = 116) ≥10 Years (n = 40) p Value Total (n = 158)
Age (years) 5.84 ± 4.91 5.39 ± 5.20 0.606 3.09 ± 3.21 12.60 ± 1.97 0.000 5.53 ± 5.08
Platelet count, high 0/33 (0.0%) 5/86 (5.8%) 0.320 4/88 (4.5%) 1/29 (3.4%) 1.000 5/119 (4.2%)
low 2/33 (6.1%) 2/86 (2.3%) 0.575 3/88 (3.4%) 1/29 (3.4%) 1.000 4/119 (3.4%)
Creatinine level, high 0/31 (0.0%) 2/83 (2.4%) 0.601 0/83 (0.0%) 2/29 (6.9%) 0.065 2/114 (1.8%)
low 0/31 (0.0%) 10/83 (12.0%) 0.060 10/83 (12.0%) 0/29 (0.0%) 0.061 10/114 (8.8%)
LDH level, high 1/33 (3.0%) 7/88 (8.0%) 0.444 7/88 (8.0%) 1/31 (3.2%) 0.454 8/121 (6.6%)
CRP, high 2/35 (5.7%) 21/92 (22.8%) 0.037 17/94 (18.1%) 6/31 (19.4%) 1.000 23/127 (18.1%)
High ALT level, high 3/33 (9.1%) 7/90 (7.8%) 1.000 9/90 (10.0%) 1/31 (3.2%) 0.295 10/123 (8.1%)
low 0/33 (0.0%) 3/90 (3.3%) 0.563 1/90 (1.1%) 2/31 (6.5%) 0.161 3/123 (2.4%)
Procalcitonin level, high 1/8 (12.5%) 12/22 (54.5%) 0.092 9/20 (45.0%) 4/10 (40.0%) 1.000 13/30 (43.3%)
D-dimer level, high 2/7 (28.6%) 9/29 (31.0%) 1.000 10/28 (35.7%) 1/8 (12.5%) 0.388 11/36 (30.6%)
CK-MB level, high 7/11 (63.6%) 8/22 (36.4%) 0.266 14/28 (50.0%) 1/5 (20.0%) 0.346 15/33 (45.5%)
1 Data are mean ± SD or number (percentage) of patients. Different denominators are due to unavailable results, or because the test is not done. Values in bold indicate statistically
significant results. Abbreviations: WBC (white blood cells), LDH (lactose dehydrogenase), CRP (C-reactive protein), ALT (alanine aminotransferase), CK-MB (creatine kinase MB fraction).
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3.2. Clinical Characteristics Based on the Presence of Symptoms
Table 1 summarizes the characteristics of all symptomatic and asymptomatic patients, and Table 2
stratifies these two groups based on their ages (<10 or ≥10 years). Twenty-three out of 24 asymptomatic
patients with follow-up remained asymptomatic throughout the time course of infection. Symptomatic
patients were more likely to be female (p = 0.054). Additionally, low creatinine levels were reported in
10 out of 83 (12.0%) symptomatic patients and none of the asymptomatic patients (p = 0.060). High
C-reactive protein (CRP) levels were reported in 21 of 92 (22.8%) symptomatic patients and only two
out of 35 (5.7%) asymptomatic cases (p = 0.037). Symptomatic cases appeared more likely to have a high
lymphocyte count (14.0% symptomatic vs. 0% asymptomatic, p = 0.019) and high procalcitonin levels
(54.5% symptomatic vs. 12.5% asymptomatic), although the latter was only of borderline significance
(p = 0.092).
Table 2. Baseline demographic, clinical characteristics, radiologic, and laboratory findings in children
according to age 1.
<10 Years (n = 116) ≥10 Years (n = 40)
Variables Asymptomatic(n = 35)
Symptomatic




(n = 25) p Value
Age (years) 3.26 ± 3.24 3.02 ± 3.22 0.722 11.87 ± 1.77 13.04 ± 1.99 0.068
Male 19/31 (61.3%) 37/78 (47.4%) 0.210 11/15 (73.3%) 13/25 (52.0%) 0.318
Female 11/30 (36.7%) 36/68 (52.9%) 0.188 3/14 (21.4%) 8/14 (57.1%) 0.120
Asymptomatic during
follow-up 14/14 (100.0%) - - 8/9 (88.9%) - -
Radiology abnormal 10/24 (41.7%) 31/51 (60.8%) 0.142 5/6 (83.3%) 12/17 (70.6%) 1.000
Typical ground-glass opacities
with patchy shadows 2/24 (8.3%) 11/51 (21.6%) 0.203 2/6 (33.3%) 4/17 (23.5%) 0.632
Typical ground-glass opacities
with consolidation 2/24 (8.3%) 0/51 (0.0%) 0.099 0/6 (0.0%) 0/17 (0.0%) -
Typical ground-glass
opacities only 0/24 (0.0%) 8/51 (15.7%) 0.049 3/6 (50.0%) 3/16 (18.8%) 0.283
Typical ground-glass opacities 5/24 (20.8%) 19/51 (37.3%) 0.191 5/6 (83.3%) 8/17 (47.1%) 0.179
Consolidation 0/24 (0.0%) 2/51 (3.9%) 0.559 0/6 (0.0%) 1/17 (5.9%) 1.000
Signs of pneumonia 9/24 (37.5%) 30/51 (58.8%) 0.136 5/6 (83.3%) 12/17 (70.6%) 1.000
Bronchitis 1/24 (4.2%) 1/51 (2.0%) 1.000 0/6 (0.0%) 0/17 (0.0%) -
Laboratory abnormal 15/26 (57.7%) 48/69 (69.6%) 0.332 2/7 (28.6%) 11/14 (78.6%) 0.056
WBC count, high 2/26 (7.7%) 10/69 (14.5%) 0.502 0/8 (0.0%) 1/24 (4.2%) 1.000
low 0/26 (0.0%) 9/69 (13.0%) 0.108 1/8 (12.5%) 4/24 (16.7%) 1.000
Neutrophil count, high 0/24 (0.0%) 3/64 (4.7%) 0.559 0/8 (0.0%) 2/22 (9.1%) 1.000
low 1/24 (4.2%) 12/64 (18.8%) 0.104 1/8 (12.5%) 2/22 (9.1%) 1.000
Lymphocyte count, high 0/26 (0.0%) 11/69 (15.9%) 0.032 0/8 (0.0%) 2/24 (8.3%) 1.000
low 1/26 (3.8%) 9/69 (13.0%) 0.276 0/8 (0.0%) 1/24 (4.2%) 1.000
Platelet count, high 0/24 (0.0%) 4/64 (6.3%) 0.333 0/8 (0.0%) 1/22 (4.5%) 1.000
low 2/24 (8.3%) 1/64 (1.6%) 0.179 0/8 (0.0%) 1/22 (4.5%) 1.000
Creatinine level, high 0/22 (0.0%) 0/61 (0.0%) - 0/8 (0.0%) 2/22 (9.1%) 1.000
low 0/22 (0.0%) 10/61 (16.4%) 0.056 0/8 (0.0%) 0/22 (0.0%) -
LDH level, high 1/24 (4.2%) 6/64 (9.4%) 0.669 0/8 (0.0%) 1/24 (4.2%) 1.000
CRP level, high 2/26 (7.7%) 15/68 (22.1%) 0.139 0/8 (0.0%) 6/24 (25.0%) 0.296
ALT level, high 2/24 (8.3%) 7/66 (10.6%) 1.000 1/8 (12.5%) 0/24 (0.0%) 0.250
low 0/24 (0.0%) 1/66 (1.5%) 1.000 0/8 (0.0%) 2/24 (8.3%) 1.000
Procalcitonin level, high 1/5 (20.0%) 8/15 (53.3%) 0.319 0/3 (0.0%) 4/7 (57.1%) 0.200
D-dimer level, high 2/5 (40.0%) 8/23 (34.8%) 1.000 0/2 (0.0%) 1/6 (16.7%) 1.000
CK-MB level, high 7/10 (70.0%) 7/18 (38.9%) 0.236 0/1 (0.0%) 1/4 (25.0%) 1.000
1 Data are mean ± SD or number (percentage) of patients. Different denominators are due to unavailable results, or
because the test is not done. Values in bold indicate statistically significant results. Abbreviations: WBC (white
blood cells), LDH (lactose dehydrogenase), CRP (C-reactive protein), ALT (alanine aminotransferase), CK-MB
(creatine kinase MB fraction).
Within children <10 years, one abnormal laboratory characteristic was observed more frequently
in the symptomatic population, i.e., high lymphocyte counts (0.0% vs. 15.9%, p = 0.032, Table 2).
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Abnormal radiological findings, such as typical ground-glass opacities only (0.0% vs. 15.7%, p = 0.049)
and ground-glass opacities with consolidation (8.3% vs. 0%, p = 0.099), occurred more often in the
symptomatic group but were not significant. Within children ≥10 years, abnormal laboratory findings
distinguished asymptomatic and symptomatic populations with borderline significance (p = 0.056).
3.3. Clinical Characteristics Based on Age
Table 1 summarizes the characteristics of patients according to age (i.e., ≥10 years or <10 years),
and Table 3 characterizes these two groups based on the presence of symptoms. The mean age for
patients below 10 years old was 3.09 years, and the mean age for patients at or above 10 was 12.60
years (Table 1). Older patients were more likely to have an increased serum creatinine (p = 0.065),
although this was not significant. Children above 10 years of age were more likely to present with
GGOs (32.0% <10 years vs. 56.5% ≥10 years, p = 0.049).
Table 3. Baseline demographic, clinical characteristics, radiologic, and laboratory findings in children
according to the presence of symptoms 1.
Asymptomatic (n = 50) Symptomatic (n = 106)
Variables <10 Years(n = 35)
≥10 Years




(n = 14) p Value
Age (years) 3.26 ± 3.24 11.87 ± 1.77 0.000 3.02 ± 3.22 13.04 ± 1.99 0.000
Male 19/31 (61.3%) 11/15 (73.3%) 0.520 37/78 (47.4%) 13/25 (52.0%) 0.819
Female 11/29 (37.9%) 3/10 (30.0%) 0.485 36/68 (52.9%) 8/14 (57.1%) 1.000
Asymptomatic during
follow-up 14/14 (100.0%) 8/9 (88.9%) 0.391 - - -
Radiology abnormal 10/24 (41.7%) 5/6 (83.3%) 0.169 31/51 (60.8%) 12/17 (70.6%) 0.568
Typical ground-glass opacities
with patchy shadows 2/24 (8.3%) 2/6 (33.3%) 0.169 11/51 (21.6%) 4/17 (23.5%) 1.000
Typical ground-glass opacities
with consolidation 2/24 (8.3%) 0/6 (0.0%) 1.000 0/51 (0.0%) 0/17 (0.0%) -
Typical ground-glass
opacities only 0/24 (0.0%) 3/6 (50.0%) 0.005 8/51 (15.7%) 3/16 (18.8%) 0.716
Typical ground-glass
opacities 5/24 (20.8%) 5/6 (83.3%) 0.009 19/51 (37.3%) 8/17 (47.1%) 0.570
Consolidation 0/24 (0.0%) 0/4 (0.0%) - 2/51 (3.9%) 1/17 (5.9%) 1.000
Signs of pneumonia 9/24 (37.5%) 5/6 (83.3%) 0.072 30/51 (58.8%) 12/17 (70.6%) 0.565
Bronchitis 1/24 (4.2%) 0/6 (0.0%) 1.000 1/51 (2.0%) 0/17 (0.0%) 1.000
Laboratory abnormal 15/24 (62.5%) 2/8 (25.0%) 0.225 48/69 (69.6%) 12/23 (52.2%) 0.206
WBC count, high 2/26 (7.7%) 0/8 (0.0%) 1.000 10/69 (14.5%) 1/23 (4.3%) 0.280
low 0/26 (0.0%) 1/8 (12.5%) 0.235 9/69 (13.0%) 4/23 (17.4%) 0.730
Neutrophil count, high 0/24 (0.0%) 0/8 (0.0%) - 3/64 (4.7%) 2/21 (9.5%) 0.593
low 1/24 (4.2%) 1/8 (12.5%) 0.444 12/64 (18.8%) 2/21 (9.5%) 0.501
Lymphocyte count, high 0/26 (0.0%) 0/8 (0.0%) - 11/69 (15.9%) 1/23 (4.3%) 0.282
low 1/26 (3.8%) 0/8 (0.0%) 1.000 9/69 (13.0%) 1/23 (4.3%) 0.442
Platelet count, high 0/24 (0.0%) 0/8 (0.0%) - 4/64 (6.3%) 1/21 (4.8%) 1.000
low 2/24 (8.3%) 0/8 (0.0%) 1.000 1/64 (1.6%) 1/21 (4.8%) 0.435
Creatinine level, high 0/22 (0.0%) 0/8 (0.0%) - 0/61 (0.0%) 2/21 (9.5%) 0.063
low 0/22 (0.0%) 0/8 (0.0%) - 10/61 (16.4%) 0/21 (0.0%) 0.058
LDH level, high 1/24 (4.2%) 0/8 (0.0%) 1.000 6/64 (9.4%) 1/23 (4.3%) 0.670
CRP level, high 2/26 (7.7%) 0/8 (0.0%) 1.000 15/68 (22.1%) 6/23 (26.1%) 0.776
ALT level, high 2/24 (8.3%) 1/8 (12.5%) 1.000 7/66 (10.6%) 0/23 (0.0%) 0.183
low 0/24 (0.0%) 0/8 (0.0%) - 1/66 (1.5%) 2/23 (8.7%) 0.163
Procalcitonin level, high 1/5 (20.0%) 0/3 (0.0%) 1.000 8/16 (50.0%) 4/7 (57.1%) 1.000
D-dimer level, high 2/5 (40.0%) 0/2 (0.0%) 1.000 8/24 (33.3%) 1/6 (16.7%) 0.637
CK-MB level, high 7/10 (70.0%) - - 7/18 (38.9%) 1/4 (25.0) 1.000
1 Data are mean ± SD or number (percentage) of patients. Different denominators are due to unavailable results, or
because the test is not done. Values in bold indicate statistically significant results. Abbreviations: WBC (white
blood cells), LDH (lactose dehydrogenase), CRP (C-reactive protein), ALT (alanine aminotransferase), CK-MB
(creatine kinase MB fraction).
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Stratified by the presence of symptoms, among asymptomatic carriers, children above or equal to
10 years were more likely to present with abnormal radiological findings. Five out of six children (83%)
above 10 years demonstrated typical ground-glass opacities with accompanying radiological signs
of pneumonia. These signs were present in 20.8% of children below 10 years (p = 0.009). Likewise,
among symptomatic cases of pediatric COVID-19, those of 10 years and above more frequently showed
increased creatinine levels (p = 0.063).
3.4. Treatment and Outcomes
No deaths were reported among symptomatic and asymptomatic populations. ICU admission was
reported in 16 of 40 cases in the symptomatic population, and 5 of 18 cases in the asymptomatic group
(Supplementary Materials Tables S1 and S2). Two were neonates delivered from SARS-CoV-2 infected
women and immediately transferred to neonatal ICU (NICU) for isolation and observation. The
reasons for ICU admission for the other three children were not reported. All 25 asymptomatic cases
with outcome data were discharged, improved, or stable following treatment. Out of 15 neonatal cases,
six cases were asymptomatic. Seven asymptomatic patients received antivirals or immunoglobulin
therapy. Three of 41 symptomatic cases with outcome data remained in the ICU at the studies’
conclusion, whereas the rest were stable or recovered. Most recovered following antiviral, antibiotic,
and/or oxygen therapy. Seven recovered without the need of supportive care. One patient with a history
of sickle cell disease developed acute respiratory distress syndrome (ARDS) in the symptomatic group,
who recovered following non-invasive ventilation, red blood cell exchange and simple transfusion,
anticoagulation therapy, and one pulse of intravenous tocilizumab [36].
4. Discussion
With the rapid and continued propagation of SARS-CoV-2 infection, it is critical that its mode of
transmission and the clinical characteristics of infection are clearly delineated. The pediatric population
has recently been examined by numerous systematic reviews [5,10,54], both to establish clinical
characteristics of pediatric infection and to evaluate the extent that children may act as asymptomatic or
mildly symptomatic carriers of the disease. Although it is suspected that mildly symptomatic pediatric
cases can become rapid transmitters of SARS-CoV-2 during the incubation period [55], we were
unable to find studies identifying predisposing risk factors or clinical characteristics distinguishing
symptomatic from asymptomatic patients. Furthermore, although many case studies were comprised
of either infants or adolescents, no study, to the best of our knowledge, separated COVID-19 pediatric
clinical features into younger and older age categories. Therefore, our study serves to (1) identify
distinguishing features of symptomatic from asymptomatic infection and (2) characterize COVID-19 in
young (<10 years) and older (10–17 years) pediatric populations. Forty-three articles published up
to 4 September 2020 were aggregated. Twenty-two were conducted in China, five in Europe, two in
the USA, and one each in Malaysia, the Republic of Korea, Vietnam, and Singapore. Twenty-three
out of 24 asymptomatic patients remained asymptomatic throughout follow-up, decreasing the
possibility that symptomatic patients experiencing an incubation period were falsely included in the
asymptomatic group.
This systematic review reveals that symptomatic infection more frequently presents with abnormal
laboratory characteristics indicative of infection. Low creatinine levels and high CRP, indicators of
abnormal renal function and inflammatory response, respectively, were present at higher rates in
symptomatic cases. Diagnostic markers more accurately determined the onset of symptoms in the
population below 10 years of age. Within this group, abnormal laboratory characteristics, especially
high lymphocyte levels, were associated with symptomatic infections, and abnormal radiological
findings, low WBC count, low neutrophil count, and low creatinine levels neared statistical significance.
This finding builds on works by Tian et al. [56], and Shi et al. [57] which linked serum creatinine
and CRP to COVID-19 mortality, suggesting these markers also coincide with symptoms in pediatric
patients. Interestingly, male sex was associated with asymptomatic infection. Previous studies in
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adults identified male sex as being associated with more severe infection, and a female predominance
in asymptomatic infections [58–60]. Dong et al. extensively examined a pediatric population and
found that males and females were equally likely to be infected, but they did not specify the effect
of sex on the manifestation of symptoms [61]. Our data suggest that, unlike in adults, male sex in
children may be associated with the absence of symptoms.
The characteristics of COVID-19 did not differ greatly between patients <10 years (including
neonates and infants) and ≥10 years. Elevated serum creatinine levels were present at higher rates in
older patients with symptoms. It is worth noting that typical GGOs were present at higher frequencies
within asymptomatic older patients (83.3%) and were only present in 20.8% of younger asymptomatic
patients. Liu et al. evaluated CT imaging as a diagnostic tool in children when nucleic acid tests were
unavailable and found less lung involvement in children. However, these results indicate that chest
CT may be more specific within an older pediatric population, which warrants further study.
Our data confirms previous findings that demonstrated milder infection in the pediatric population.
No deaths were reported, and most cases recovered fully. Asymptomatic patients rarely received
treatment, and symptomatic patients typically recovered well with antibiotics, antivirals, and oxygen
therapy. For both asymptomatic and symptomatic populations, ICU admission occurred at similar
rates. Only one ARDS was observed, which was consistent with previous research that complication
rate of children was <2% as compared to 5% in adults [11,30,54]. The most common symptoms,
when present, were fever, cough, and vomiting. Cases of neonatal COVID-19 were reported in 15 cases
across six studies [14,15,18,19,37,39], and prognoses and symptoms were similar to other age groups,
with six neonatal infections being asymptomatic.
There is still not enough information about the clinical features, laboratory, and radiologic findings
of children, infants, and neonates COVID-19 infections. Fortunately, the pediatric population is
deemed to have milder symptoms and better prognosis than adults. Thus, clinicians should be alert
to asymptomatic SARS-CoV-2 infected children. Children cannot stay at home forever, and they
need more definite preventive and treatment measures than just hand hygiene and supportive care.
Therefore, continuous updates on the susceptibility and mechanisms on childhood COVID-19 infection
are important.
Our study has several limitations. First, blood laboratory samples and CT were taken at different
time points of infection for different patients. It is possible that as disease progressed from the contraction
of illness to the onset of symptoms, laboratory characteristics and radiological features could have
changed among cases. Second, included articles were not prospective, which would have helped in
identifying risk factors predisposing certain children to symptomatic infection. Third, most articles
originated from China, as studies from other countries with regards to children were rare. Furthermore,
we found low numbers of cases within some categories of age and symptoms. For example, the subset
of symptomatic patients ≥10 years with reported GGOs included only three cases, which could have
interfered with statistical reliability. Fourth, multisystem inflammatory syndrome, a severe pediatric
condition associated with COVID-19, was not specified during data extraction. Although the condition
is rare, with a total of 570 reported to the CDC as of July 2020, it is possible that signs and symptoms
of multisystem inflammatory syndrome in one or more samples included in our analysis could have
altered our results [62]. Fifth, although this study aggregates evidence sufficiently to achieve a power
of 0.75–0.85 for comparisons of asymptomatic and symptomatic or younger and older children, some
subgroup comparisons performed using Fisher’s exact test were unable to achieve this level of power,
ranging from as low as 0.15 for GGO comparisons in asymptomatic vs. symptomatic children below
10 years to as high as 0.90 for GGO comparisons in above vs. below age 10 in asymptomatic children.
Finally, we were unable to perform contact-tracing on our cases to evaluate the transmissibility of the
symptomatic and asymptomatic cases. However, the strength of this systematic review is that it is
the first, to our knowledge, to aggregate evidence of symptomatic and asymptomatic SARS-CoV-2
infection in children of varying ages.
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5. Conclusions
Our systematic review summarizes the clinical features of 158 pediatric COVID-19 patients
stratified by both the presence of symptoms and by groups above and below 10 years old. We report
no mortalities, and most cases recovered. However, males were more likely to have asymptomatic
infection, and abnormal lab findings better distinguished symptomatic from asymptomatic pediatric
COVID-19. The clinical features of the older and younger age groups were similar, but typical GGOs
were present more often in older asymptomatic infections. Furthermore, prospective studies could
reveal predisposing factors of symptomatic or asymptomatic infection and guide prevention efforts.
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